PTEN and glioblastoma: The report has shown that mutated PTEN accounted for 31% of glioblastoma cell lines and xenografts, 100% of prostate cancer cell lines, 6% of breast cancer cell lines and xenografts, and 17% of primary glioblastomas [24].